Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Recruiting 72Active not recruiting 30Not yet recruiting 25Completed 24Terminated 9Enrolling by invitation 4Withdrawn 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 28Neoplasms 26Prostatic Neoplasms 22Colorectal Neoplasms 18Head and Neck Neoplasms 14Pancreatic Neoplasms 12Melanoma 10Lung Neoplasms 10Brain Neoplasms 10Neoplasm Metastasis 9Carcinoma, Renal Cell 9Squamous Cell Carcinoma of Head and Neck 8Carcinoma, Non-Small-Cell Lung 8Triple Negative Breast Neoplasms 7Recurrence 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Multiple Myeloma 7Lymphoma, Follicular 7Lymphoma 7Glioblastoma 7Leukemia, Myeloid, Acute 6Leukemia 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5Ovarian Neoplasms 5Lymphoma, B-Cell 5Kidney Neoplasms 5Hematologic Neoplasms 5Sarcoma 4Liver Neoplasms 4

Interventions

Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Esophageal Squamous Cell Carcinoma × 1 year × Clear all
NCT05312372 2026-02-17

S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC

Servier

Phase 1/2 Withdrawn
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06420908 2025-08-26

Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)

Hebei Medical University Fourth Hospital

Phase NA Withdrawn
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡